# Primary Immunodeficiency Diseases (PID) FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/primary-immunodeficiency-diseases-pid

> 2 upcoming FDA catalysts in primary Immunodeficiency Diseases (PID): TAK-881 (TAK) on May to Aug 2028 (topline data readout); TAK-881 (TAK) on May 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 30, 2025 | [TAK-771 primary completion](https://sec-api.dev/pdufa/tak-771) | TAK | Primary Immunodeficiency Diseases (PID) | completed | "NCT05513586 (A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-30 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-05-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05513586)) |
| January 20, 2026 | [TAK-881 primary completion](https://sec-api.dev/pdufa/tak-881) | TAK | Primary Immunodeficiency Diseases (PID) | completed | "NCT05755035 (A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-01-20 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-09-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05755035)) |
| May 19, 2026 | [TAK-771 topline data readout](https://sec-api.dev/pdufa/tak-771) | TAK | Primary Immunodeficiency Diseases (PID) | completed | "NCT05513586 (A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-30 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-05-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05513586?tab=results)) |
| September 30, 2026 | [TAK-881 topline data readout](https://sec-api.dev/pdufa/tak-881) | TAK | Primary Immunodeficiency Diseases (PID) | completed | "NCT05755035 (A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-01-20 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-09-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05755035?tab=results)) |
| May to Aug 2028 | [TAK-881 topline data readout](https://sec-api.dev/pdufa/tak-881) | TAK | Primary Immunodeficiency Diseases (PID) | scheduled | "NCT06076642 (A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-16 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06076642)) |
| May 2028 | [TAK-881 primary completion](https://sec-api.dev/pdufa/tak-881) | TAK | Primary Immunodeficiency Diseases (PID) | scheduled | "NCT06076642 (A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-16 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06076642)) |

## Drugs

- [TAK-771](https://sec-api.dev/pdufa/tak-771) (TAK)
- [TAK-881](https://sec-api.dev/pdufa/tak-881) (TAK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/primary-immunodeficiency-diseases-pid.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Primary Immunodeficiency Diseases (PID) FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/primary-immunodeficiency-diseases-pid

```bibtex
@misc{secapidev_indications_primary_immunodeficiency_diseases_pid_20261116,
  title        = {Primary Immunodeficiency Diseases (PID) FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/primary-immunodeficiency-diseases-pid}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_primary_immunodeficiency_diseases_pid_20261116","title":"Primary Immunodeficiency Diseases (PID) FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/primary-immunodeficiency-diseases-pid","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
